Cargando…

US/MR Bimodal Imaging-Guided Bio-Targeting Synergistic Agent for Tumor Therapy

PURPOSE: Breast cancer is detrimental to the health of women due to the difficulty of early diagnosis and unsatisfactory therapeutic efficacy of available breast cancer therapies. High intensity focused ultrasound (HIFU) ablation is a new method for the treatment of breast tumors, but there is a pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Fujie, Wang, Lu, Tang, Yu, Wang, Yaotai, Li, Ningshan, Wang, Disen, Zhang, Zhong, Lin, Li, Du, Yan, Ou, Xia, Zou, Jianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270014/
https://www.ncbi.nlm.nih.gov/pubmed/35814614
http://dx.doi.org/10.2147/IJN.S363645
_version_ 1784744361718710272
author Jiang, Fujie
Wang, Lu
Tang, Yu
Wang, Yaotai
Li, Ningshan
Wang, Disen
Zhang, Zhong
Lin, Li
Du, Yan
Ou, Xia
Zou, Jianzhong
author_facet Jiang, Fujie
Wang, Lu
Tang, Yu
Wang, Yaotai
Li, Ningshan
Wang, Disen
Zhang, Zhong
Lin, Li
Du, Yan
Ou, Xia
Zou, Jianzhong
author_sort Jiang, Fujie
collection PubMed
description PURPOSE: Breast cancer is detrimental to the health of women due to the difficulty of early diagnosis and unsatisfactory therapeutic efficacy of available breast cancer therapies. High intensity focused ultrasound (HIFU) ablation is a new method for the treatment of breast tumors, but there is a problem of low ablation efficiency. Therefore, the improvement of HIFU efficiency to combat breast cancer is immediately needed. This study aimed to describe a novel anaerobic bacteria-mediated nanoplatform, comprising synergistic HIFU therapy for breast cancer under guidance of ultrasound (US) and magnetic resonance (MR) bimodal imaging. METHODS: The PFH@CL/Fe(3)O(4) nanoparticles (NPs) (Perfluorohexane (PFH) and superparamagnetic iron oxides (SPIO, Fe(3)O(4)) with cationic lipid (CL) NPs) were synthesized using the thin membrane hydration method. The novel nanoplatform Bifidobacterium bifidum-mediated PFH@CL/Fe(3)O(4) NPs were constructed by electrostatic adsorption. Thereafter, US and MR bimodal imaging ability of B. bifidum-mediated PFH@CL/Fe(3)O(4) NPs was evaluated in vitro and in vivo. Finally, the efficacy of HIFU ablation based on B. bifidum-PFH@CL/Fe(3)O(4) NPs was studied. RESULTS: B. bifidum combined with PFH@CL/Fe(3)O(4) NPs by electrostatic adsorption and enhanced the tumor targeting ability of PFH@CL/Fe(3)O(4) NPs. US and MR bimodal imaging clearly displayed the distribution of the bio-targeting nanoplatform in vivo. It was conducive for accurate and effective guidance of HIFU synergistic treatment of tumors. Furthermore, PFH@CL/Fe(3)O(4) NPs could form microbubbles by acoustic droplet evaporation and promote efficiency of HIFU ablation under guidance of bimodal imaging. CONCLUSION: A bio-targeting nanoplatform with high stability and good physicochemical properties was constructed. The HIFU synergistic agent achieved early precision imaging of tumors and promoted therapeutic effect, monitored by US and MR bimodal imaging during the treatment process.
format Online
Article
Text
id pubmed-9270014
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92700142022-07-09 US/MR Bimodal Imaging-Guided Bio-Targeting Synergistic Agent for Tumor Therapy Jiang, Fujie Wang, Lu Tang, Yu Wang, Yaotai Li, Ningshan Wang, Disen Zhang, Zhong Lin, Li Du, Yan Ou, Xia Zou, Jianzhong Int J Nanomedicine Original Research PURPOSE: Breast cancer is detrimental to the health of women due to the difficulty of early diagnosis and unsatisfactory therapeutic efficacy of available breast cancer therapies. High intensity focused ultrasound (HIFU) ablation is a new method for the treatment of breast tumors, but there is a problem of low ablation efficiency. Therefore, the improvement of HIFU efficiency to combat breast cancer is immediately needed. This study aimed to describe a novel anaerobic bacteria-mediated nanoplatform, comprising synergistic HIFU therapy for breast cancer under guidance of ultrasound (US) and magnetic resonance (MR) bimodal imaging. METHODS: The PFH@CL/Fe(3)O(4) nanoparticles (NPs) (Perfluorohexane (PFH) and superparamagnetic iron oxides (SPIO, Fe(3)O(4)) with cationic lipid (CL) NPs) were synthesized using the thin membrane hydration method. The novel nanoplatform Bifidobacterium bifidum-mediated PFH@CL/Fe(3)O(4) NPs were constructed by electrostatic adsorption. Thereafter, US and MR bimodal imaging ability of B. bifidum-mediated PFH@CL/Fe(3)O(4) NPs was evaluated in vitro and in vivo. Finally, the efficacy of HIFU ablation based on B. bifidum-PFH@CL/Fe(3)O(4) NPs was studied. RESULTS: B. bifidum combined with PFH@CL/Fe(3)O(4) NPs by electrostatic adsorption and enhanced the tumor targeting ability of PFH@CL/Fe(3)O(4) NPs. US and MR bimodal imaging clearly displayed the distribution of the bio-targeting nanoplatform in vivo. It was conducive for accurate and effective guidance of HIFU synergistic treatment of tumors. Furthermore, PFH@CL/Fe(3)O(4) NPs could form microbubbles by acoustic droplet evaporation and promote efficiency of HIFU ablation under guidance of bimodal imaging. CONCLUSION: A bio-targeting nanoplatform with high stability and good physicochemical properties was constructed. The HIFU synergistic agent achieved early precision imaging of tumors and promoted therapeutic effect, monitored by US and MR bimodal imaging during the treatment process. Dove 2022-07-04 /pmc/articles/PMC9270014/ /pubmed/35814614 http://dx.doi.org/10.2147/IJN.S363645 Text en © 2022 Jiang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Jiang, Fujie
Wang, Lu
Tang, Yu
Wang, Yaotai
Li, Ningshan
Wang, Disen
Zhang, Zhong
Lin, Li
Du, Yan
Ou, Xia
Zou, Jianzhong
US/MR Bimodal Imaging-Guided Bio-Targeting Synergistic Agent for Tumor Therapy
title US/MR Bimodal Imaging-Guided Bio-Targeting Synergistic Agent for Tumor Therapy
title_full US/MR Bimodal Imaging-Guided Bio-Targeting Synergistic Agent for Tumor Therapy
title_fullStr US/MR Bimodal Imaging-Guided Bio-Targeting Synergistic Agent for Tumor Therapy
title_full_unstemmed US/MR Bimodal Imaging-Guided Bio-Targeting Synergistic Agent for Tumor Therapy
title_short US/MR Bimodal Imaging-Guided Bio-Targeting Synergistic Agent for Tumor Therapy
title_sort us/mr bimodal imaging-guided bio-targeting synergistic agent for tumor therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270014/
https://www.ncbi.nlm.nih.gov/pubmed/35814614
http://dx.doi.org/10.2147/IJN.S363645
work_keys_str_mv AT jiangfujie usmrbimodalimagingguidedbiotargetingsynergisticagentfortumortherapy
AT wanglu usmrbimodalimagingguidedbiotargetingsynergisticagentfortumortherapy
AT tangyu usmrbimodalimagingguidedbiotargetingsynergisticagentfortumortherapy
AT wangyaotai usmrbimodalimagingguidedbiotargetingsynergisticagentfortumortherapy
AT liningshan usmrbimodalimagingguidedbiotargetingsynergisticagentfortumortherapy
AT wangdisen usmrbimodalimagingguidedbiotargetingsynergisticagentfortumortherapy
AT zhangzhong usmrbimodalimagingguidedbiotargetingsynergisticagentfortumortherapy
AT linli usmrbimodalimagingguidedbiotargetingsynergisticagentfortumortherapy
AT duyan usmrbimodalimagingguidedbiotargetingsynergisticagentfortumortherapy
AT ouxia usmrbimodalimagingguidedbiotargetingsynergisticagentfortumortherapy
AT zoujianzhong usmrbimodalimagingguidedbiotargetingsynergisticagentfortumortherapy